STOCK TITAN

United Therapeutics (UTHR) grants director 2,380 stock options at $527.07

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics Corp director Louis W. Sullivan received an annual non-employee director stock option award covering 2,380 shares of common stock at an exercise price of $527.07 per share. The options vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027, and expire on July 22, 2033. After this filing, he holds 2,983 common shares directly and 1,457 shares indirectly through a trust over which he has sole investment and voting power; totals were updated to correct a prior underreporting of 590 trust shares.

Positive

  • None.

Negative

  • None.
Insider SULLIVAN LOUIS W
Role Director
Type Security Shares Price Value
Grant/Award Stock Option F3, F4 2,380 $0.00 $0.00
holding Common Stock F1 -- -- --
holding Common Stock F2 -- -- --
Holdings After Transaction: Stock Option — 2,380 shares (Direct); Common Stock — 2,983 shares (Direct); Common Stock — 1,457 shares (Indirect, by Trust)
Footnotes (4)
  1. F1. Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026.
  2. F2. These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.
  3. F3. Annual non-employee director award.
  4. F4. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Options Granted 2,380 options Annual non-employee director stock option award to Louis W. Sullivan
Exercise Price $527.07 per share Conversion or exercise price of the granted stock options
Option Expiration July 22, 2033 Expiration date of the stock options granted
Expected Vesting Date June 25, 2027 Anticipated date of the next Annual Meeting, when awards may fully vest
Direct Common Shares 2,983 shares Total UTHR common stock held directly after reported transactions
Indirect Trust Shares 1,457 shares Common stock held indirectly by a trust with sole voting and investment power
Clerical Error Adjustment 590 shares Previously underreported indirect trust holdings corrected in this filing
Stock Option financial
"security_title: Stock Option; underlying security is Common Stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Annual non-employee director award financial
"Footnote F3: Annual non-employee director award."
Annual Meeting of Shareholders regulatory
"become fully vested on the earlier to occur of ... the date of the next Annual Meeting of Shareholders"
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
indirect holding financial
"caused the reporting person's indirect holding of common stock (by trust) to be underreported"
voting power financial
"held indirectly by a trust over which the reporting person has sole investment power and sole voting power"
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did United Therapeutics (UTHR) report for Louis W. Sullivan?

Louis W. Sullivan received an annual non-employee director stock option award for 2,380 shares at an exercise price of $527.07 per share. The award is compensation-related, not an open-market purchase or sale, and vests based on director service and the next shareholder meeting.

What are the key terms of the new stock options granted at UTHR?

The grant consists of 2,380 stock options with an exercise price of $527.07 per share, expiring on July 22, 2033. The options vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, expected by June 25, 2027.

How many United Therapeutics (UTHR) shares does Louis W. Sullivan own after this filing?

Following the reported transactions, Louis W. Sullivan holds 2,983 shares of UTHR common stock directly and 1,457 shares indirectly through a trust. The filing notes he has sole investment and voting power over the trust-held shares.

Did the UTHR filing correct any prior reporting errors for Louis W. Sullivan?

Yes. A footnote states that Sullivan’s indirect holdings by trust were previously underreported by 590 shares due to a clerical error. The totals disclosed in this filing have been updated to reflect the additional trust-held shares.

Are Louis W. Sullivan’s new UTHR options tied to a trading plan under Rule 10b5-1?

The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and the footnotes describe the grant as an annual non-employee director award. The transactions reflect compensation awards rather than sales or purchases under a pre-arranged trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SULLIVAN LOUIS W

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock2,983(1)D
Common Stock1,457Iby Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$527.0707/22/2026A2,380(3)06/25/2027(4)07/22/2033Common Stock2,380$0.002,380D
Explanation of Responses:
1. Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026.
2. These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.
3. Annual non-employee director award.
4. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney07/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)